Intra-Cellular Therapies, Inc.

NasdaqGS:ITCI 주식 보고서

시가총액: US$9.5b

Intra-Cellular Therapies 과거 수익 실적

과거 기준 확인 0/6

Intra-Cellular Therapies은 연평균 5.8%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 연평균 0.2%의 비율로 수입이 감소했습니다. 매출은 연평균 63.9%의 비율로 증가했습니다.

주요 정보

5.8%

수익 성장률

15.8%

EPS 성장률

Pharmaceuticals 산업 성장6.0%
매출 성장률63.9%
자기자본 수익률-7.5%
순이익-14.1%
최근 수익 업데이트30 Sep 2024

최근 과거 실적 업데이트

Recent updates

Revenues Tell The Story For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) As Its Stock Soars 26%

Nov 07
Revenues Tell The Story For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) As Its Stock Soars 26%

Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Strong Position To Grow Its Business

Sep 22
Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Strong Position To Grow Its Business

Peaking Back In On Intra-Cellular Therapies

Sep 04

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Aug 10
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

With Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) It Looks Like You'll Get What You Pay For

Jul 27
With Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) It Looks Like You'll Get What You Pay For

Intra-Cellular Brightens MDD Outlook With Caplyta Success

Jun 19

Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data

Apr 16

Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is On The Mark

Apr 09
Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is On The Mark

We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Mar 17
We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Intra-Cellular Therapies Is On Fire

Mar 11

Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'

Feb 11

Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Price Is Out Of Tune With Revenues

Dec 24
Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Price Is Out Of Tune With Revenues

We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Nov 11
We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Can Afford To Invest In Growth

Aug 07
Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Can Afford To Invest In Growth

Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation

May 09
Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation

After Leaping 31% Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Are Not Flying Under The Radar

Apr 17
After Leaping 31% Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Are Not Flying Under The Radar

We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate

Jan 31
We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate

Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans

Oct 25
Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans

Intra-Cellular Therapies: What Lies Ahead

Sep 20

Intra-Cellular cut to Neutral at Goldman on trends for antipsychotic drug

Aug 22

Intra-Cellular Therapies GAAP EPS of -$0.92 misses by $0.15, revenue of $55.6M beats by $6.98M

Aug 09

We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely

Jul 09
We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely

Intra-Cellular Therapies: A Dramatic Story

Jun 18

Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth

Apr 03
Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth

Intra-Cellular: Not Participating In A Bear Market

Mar 31

Intra-Cellular; Long-Term To Own With A Few FDA Approvals And Ability To Expand

Mar 08

수익 및 비용 분석

Intra-Cellular Therapies 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

NasdaqGS:ITCI 수익, 비용 및 수입 (USD Millions )
날짜수익수익G+A 비용R&D 비용
30 Sep 24614-864710
30 Jun 24565-844450
31 Mar 24514-1114240
31 Dec 23464-1404100
30 Sep 23420-1554000
30 Jun 23366-1843830
31 Mar 23311-2283820
31 Dec 22250-2563590
30 Sep 22188-2983440
30 Jun 22138-3213260
31 Mar 22103-3042950
31 Dec 2184-2842730
30 Sep 2171-2592510
30 Jun 2156-2372330
31 Mar 2138-2322050
31 Dec 2023-2271860
30 Sep 2010-2071510
30 Jun 203-1871130
31 Mar 201-160870
31 Dec 190-148650
30 Sep 190-148510
30 Jun 190-155440
31 Mar 190-154350
31 Dec 180-155300
30 Sep 180-145270
30 Jun 180-126240
31 Mar 180-106240
31 Dec 170-98240
30 Sep 170-95250
30 Jun 170-102260
31 Mar 170-116260
31 Dec 160-116250
30 Sep 160-118240
30 Jun 160-120220
31 Mar 160-110190
31 Dec 150-105180
30 Sep 150-91150
30 Jun 150-65140
31 Mar 150-48120
31 Dec 141-31100
30 Sep 141-2490
30 Jun 142-2280
31 Mar 142-2670
31 Dec 133-2760

양질의 수익: ITCI 은(는) 현재 수익성이 없습니다.

이익 마진 증가: ITCI 은(는) 현재 수익성이 없습니다.


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: ITCI 은(는) 수익성이 없지만 지난 5년 동안 연간 5.8% 의 비율로 손실을 줄였습니다.

성장 가속화: 현재 수익성이 없기 때문에 ITCI 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: ITCI 은(는) 수익성이 없어 지난 해 수익 성장을 Pharmaceuticals 업계( 54.6% )와 비교하기 어렵습니다.


자기자본 수익률

높은 ROE: ITCI 현재 수익성이 없기 때문에 마이너스 자본 수익률( -7.54% )을 갖습니다.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기